comparemela.com

Latest Breaking News On - Simvastatin - Page 1 : comparemela.com

Simvastatin does not improve outcomes in patients critically ill with COVID-19

1. In this randomized controlled trial, high-dose simvastatin did not reduce the need for organ support among critically ill patients with coronavirus disease 2019 (COVID-19). 2. High-dose simvastatin was associated with increased rates of serious adverse events amongst critically ill patients with COVID-19. Evidence Rating Level: 1 (Excellent) Study Rundown: Among critically ill patients who

#VisualAbstract: Simvastatin is non-superior to control in critically ill COVID-19 patients

Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

MyJournals org - Science - IJMS, Vol 24, Pages 10414: Repurposing Simvastatin in Parkinson s Disease Model: Protection Is throughout Modulation of the Neuro-Inflammatory Response in the Substantia nigra (International Journal of Molecular Sciences)

MyJournals.org - Science - IJMS, Vol. 24, Pages 10414: Repurposing Simvastatin in Parkinson’s Disease Model: Protection Is throughout Modulation of the Neuro-Inflammatory Response in the Substantia nigra (International Journal of Molecular Sciences)

Amazon Prime Launches $5-a-Month RxPass for Drug Prescriptions

Amazon RxPass covers 60 generic medications prescribed for 80 common conditions like depression and high cholesterol. Customers don't need insurance to get it.

Simvastatin could be new treatment option for patients with non-segmental vitiligo and dyslipidemia: Study

Egypt: For patients with nonsegmental vitiligo (NSV) and dyslipidemia, a daily regimen of simvastatin 80 mg could be a helpful treatment, is the conclusion drawn from a study published in Dermatologic.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.